Sign In
Buy LEGN
$35.98
-0.300 (-0.83%)
At Close: Jun 03, 2026
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
07:37am, Wednesday, 10'th Dec 2025
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Ensign Peak Advisors Inc
04:20am, Tuesday, 02'nd Dec 2025
Ensign Peak Advisors Inc trimmed its position in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 30.4% during the second quarter, according to the company in its most recent 13F filing with
Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?
02:38pm, Tuesday, 25'th Nov 2025
Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem"
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
12:08pm, Thursday, 13'th Nov 2025
31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation
Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript
12:51pm, Wednesday, 12'th Nov 2025
Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Di
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
11:05am, Monday, 03'rd Nov 2025
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
08:00am, Wednesday, 29'th Oct 2025
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET o
US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy
06:36pm, Friday, 10'th Oct 2025
The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
11:47pm, Tuesday, 09'th Sep 2025
Legend Biotech Corporation (NASDAQ:LEGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Ying Huang - CEO & Director Conference Call Partici
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
08:00am, Monday, 18'th Aug 2025
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the C
What Moved Markets This Week
07:18am, Saturday, 16'th Aug 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
02:12pm, Thursday, 14'th Aug 2025
New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with str
Legend Biotech Corporation (LEGN) Q2 2025 Earnings Call Transcript
01:41pm, Monday, 11'th Aug 2025
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Alan S. Bash - President of CARVYKTI® Caroline LeCates Paul - Associate Dire
